Yahoo Finance • 8 hours ago
Johnson & Johnson (JNJ) shares have edged up roughly 0.4% since yesterday, continuing an upward stretch that has seen the stock climb 6% over the past month and 20% in the past three months. Investors are keeping an eye on how these steady... Full story
Yahoo Finance • 15 hours ago
Icotrokinra, an oral interleukin-23 antagonist peptide being developed by Protagonist Therapeutics ( PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 17 hours ago
Johnson & Johnson stock has recently seen its consensus analyst price target lifted from $179.64 to $185.13, marking an increase of approximately $5.49 as market sentiment improves. This upward revision comes as analysts anticipate renewed... Full story
Yahoo Finance • 19 hours ago
[Business on Wall Street in Manhattan] Pgiam/iStock via Getty Images CG Oncology (NASDAQ:CGON [https://seekingalpha.com/symbol/CGON]), a biotech focused on non-muscle invasive bladder cancer (NMIBC), traded ~9% higher on Wednesday after G... Full story
Yahoo Finance • yesterday
Johnson & Johnson (NYSE:JNJ) is included among the 13 Most Profitable Dividend Stocks to Buy Right Now.Johnson & Johnson (JNJ): A Cornerstone Among the Most Profitable Dividend Stocks Johnson & Johnson (NYSE:JNJ) is one of America’s most... Full story
Yahoo Finance • 2 days ago
[Janssen Pharmaceuticals office in Brisbane, California, USA] JHVEPhoto/iStock Editorial via Getty Images * Legend Biotech (NASDAQ:LEGN [https://seekingalpha.com/symbol/LEGN]) and Johnson & Johnson's (NYSE:JNJ [https://seekingalpha.com/... Full story
Yahoo Finance • 2 days ago
Dean Omar Branham Shirley secures largest-ever mesothelioma talc verdict LOS ANGELES, October 07, 2025--(BUSINESS WIRE)--A Los Angeles County jury has returned damages totaling $966 million, including $950 million in punitive damages, to... Full story
Yahoo Finance • 2 days ago
Health care stocks edged lower late Tuesday afternoon, with the NYSE Health Care Index and the Healt PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 2 days ago
[Judges gavel in courtroom legal trial and law background] Johnson & Johnson (NYSE:JNJ [https://seekingalpha.com/symbol/JNJ]) will have to pay $966M after a jury in Los Angeles issued a verdict in favor of a woman who claimed that the pha... Full story
Yahoo Finance • 2 days ago
Prudential Financial (PRU) has landed in the spotlight as investors take a closer look at its fundamentals. This follows news of shrinking net premiums, tepid book value growth, and a rising debt-to-equity ratio. See our latest analysis f... Full story
Yahoo Finance • 2 days ago
Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated with the highest dose achieving endoscopic improvement at Week 12 in the Phase 2b ANTHEM-UC study These data support the promise... Full story
Yahoo Finance • 2 days ago
Patients treated with subcutaneous TREMFYA® achieved clinically meaningful results in both clinical remission (36.7%) and endoscopic remission (25.9%) at Week 48 in the Phase 3 ASTRO study Clinical and endoscopic outcomes were demonstrate... Full story
Yahoo Finance • 2 days ago
Studies presented at #Academy25 reveal that ACUVUE OASYS MAX 1-Day for ASTIGMATISM outperformed Dailies Total1® for Astigmatism in patient reported outcomes related to vision and comfort. Research highlights that the latest ACUVUE contact... Full story
Yahoo Finance • 3 days ago
DelveInsight Business Research LLP The diffuse cutaneous systemic sclerosis market landscape is evolving from conventional symptom-focused strategies toward therapies that specifically target fibrosis and immune modulation, addressing a s... Full story
Yahoo Finance • 3 days ago
In the past week, U.S. Orthopaedic Partners announced a collaboration with Johnson & Johnson, selecting the medtech company as its official vendor for total joint products across its clinical platform after a surgeon-led evaluation of prod... Full story
Yahoo Finance • 3 days ago
- Basil’s AI-powered Safety Signaling helps manufacturers identify risks associated with recalls, accelerate corrective actions, and strengthen patient safety. - Advanced MedTech intelligence platform already trusted by Johnson & Johnson,... Full story
Yahoo Finance • 4 days ago
Wall Street’s broader market averages closed mixed on Friday as market participants digested the U.S. government shutdown for the third day. For the week, the Dow, S&P 500, and Nasdaq Composite advanced by 1.1%, 1.08%, and 1.32%, respecti... Full story
Yahoo Finance • 5 days ago
Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer put under the microscope. Cramer recalled his discussion with the company’s CEO, and commented: “What else might work? Last Friday on the show, we had Joaquin Duato. He’s the CE... Full story
Yahoo Finance • 5 days ago
[President Trump Delivers An Announcement From The Oval Office] Win McNamee/Getty Images News The world’s biggest pharma companies recorded their best weekly performance in years on Friday after Pfizer (NYSE:PFE [https://seekingalpha.com/... Full story
Yahoo Finance • 5 days ago
The S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link%7Cfirst_level_url%3Anews]) closed in the green on Friday, while Nasdaq (COMP:IND [https://seekingalpha.... Full story